U01 Research Project Cooperative Agreement
Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01)
This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator current awardee of the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Data Coordinating Center (DCC) (AMP T2D-GENES DCC). The AMP T2D-GENES consortium will consist of the DCC as well as participating sites being solicited by the companion FOA. The mission of AMP T2D-GENES is to characterize the genetic variations in human genomic regions that have been putatively associated with type 2 diabetes (T2D) and conduct follow-up functional studies of particular genetic variants. This is a one-time FOA to provide funds to the AMP T2D-GENES DCC to continue the development of the web portal and deposit, aggregate and process the data generated, as part of an ongoing consortium of AMP T2D-GENES investigators as well as T2D-GENES community, for a maximum of five years, contingent on satisfactory performance. To support the conduct of these studies, AMP T2D-GENES DCC will coordinate manage and support the centers and provide the administrative infrastructure for the NIDDK-funded AMP T2D-GENES consortium. The AMP T2D-GENES DCC will build on and expand the previous work of the T2D GENES consortium.
|Notice(s) for this Opportunity|
|Letter of Intent Due Date|
June 18, 2014
|Application Due Date|
July 18, 2014, by 5:00 PM local time of applicant organization.